Layer 01 — Available today
Proven infrastructure
Order intake, eligibility, claim pre-scrubbing, coding rule support, reconciliation, and automated follow-up, delivered through established technology partners.
Diagnostic Management & Consulting Group
From Diagnostic Innovation to Reimbursed Revenue.
DMC integrates the commercialization pathway for advanced diagnostics — from assay readiness and reimbursement strategy through market access, launch, and specialized revenue-cycle execution.
Senior expertise
Senior expertise, directly engaged — leadership with decades of laboratory and commercialization experience.
Assay
Validate
Code
Cover
Commercialize
Bill
Collect
Expand
The problem
Great science is only the beginning.
DMC helps innovative diagnostic companies navigate the complex path from assay readiness to sustainable reimbursement and commercial adoption.
Advanced diagnostic innovation is moving faster than the reimbursement and commercialization infrastructure meant to support it. A promising assay can succeed scientifically and still stall commercially.
The path from scientific readiness to payment is fragmented across a dozen specialties, vendors, and internal functions — and every handoff costs time, context, and margin.
How we integrate itAnalytical validation
Coding strategy
Evidence development
Payer coverage
Reimbursement
Market launch
Physician adoption
Claims
Denials
Appeals
Collections
Validation ≠ Coding ≠ Coverage ≠ Reimbursement ≠ Collections
Why DMC
Integrated. Specialized. Scalable.
Integrated
One senior team accountable from assay readiness through collections — instead of five vendors each optimizing their own stage.
Specialized
Built exclusively around advanced diagnostics, where coverage policy, evidence, and coding drive the economics of the business.
Scalable
Recurring diagnostic problems are converted into repeatable workflows and, over time, proprietary intelligence — operating leverage a traditional consulting model does not have.
The commercialization continuum
One integrated pathway, not five disconnected services.
These stages are distinct disciplines with distinct evidence, stakeholders, and failure modes. DMC's value is integrating them around the economic life of an assay.
01
Assay Readiness & Validation
Analytical-validation planning, documentation, scientific readiness, and gap assessment.
Explore
02
Coding & Reimbursement Strategy
Coding pathway evaluation, including PLA/CPT where applicable, with the documentation and evidence to support payment.
Explore
03
Coverage & Market Access
Payer strategy, evidence requirements, coverage planning, and MolDX-related considerations where applicable.
Explore
04
Commercialization & Adoption
Go-to-market strategy, physician adoption, health-system relationships, channel partnerships, and enterprise contracting.
Explore
05
Revenue Cycle & Collections
Eligibility, prior authorization, coding integrity, claim scrubbing, denials, appeals, payer follow-up, reconciliation, and collections.
Explore
Integrated
Assay → Validate → Code → Cover → Commercialize → Bill → Collect → Expand.
See the approachLifecycle value
One assay can become a much larger relationship.
DMC can enter through a difficult new diagnostic program, prove value across reimbursement and commercialization, and expand into additional assays and broader laboratory revenue-cycle support.
New Assay
Strategic Trust
Assay-Level RCM
Additional Assays
Enterprise RCM
The relationship also runs in the other direction — an existing laboratory relationship often surfaces new assay opportunities that require validation, reimbursement, and commercialization support.
How the model compounds
Technology strategy
Proven RCM infrastructure underneath.
Proprietary diagnostics intelligence on top.
Expert-led. AI-enabled. DMC's direction is to build a diagnostics-specific intelligence layer on top of revenue-cycle infrastructure that already works — rather than rebuilding commodity systems. It is a deliberate, capital-efficient strategy: leverage what is proven, and build proprietary capability only where advanced diagnostics are genuinely different.
Layer 02 — In development
Diagnostics intelligence
Assay-aware coding, coverage-policy, and denial logic for molecular, genomic, and specialty testing — the context generic RCM technology does not carry.
The thesis
Expertise into leverage
Specialized diagnostic expertise converted into repeatable workflows and, over time, proprietary intelligence — operating leverage beyond a traditional consulting model.
The intelligence layer is in development and is described here as strategy, not as a completed platform. DMC does not own the underlying third-party infrastructure, and coding and reimbursement decisions remain under human review. Technology supports expert judgment; it does not guarantee payer outcomes.
Who we serve
Built for advanced diagnostics with complex paths to market.
- →Novel assay developers
- →Molecular & specialty laboratories
- →Genomics companies
- →Laboratories launching new tests
- →Complex reimbursement problems
- →International market entry
Begin the conversation